Dr. Gearóid Tuohy

Advernum Biotechnologies Inc., (NASDAQ: ADVM) expects to enrol Phase 2 patients for a treatment for DME using the aflibercept gene.

A US biotechnology company, Advernum Biotechnologies Inc., (NASDAQ:ADVM), has announced the enrolment of a Phase 2 study for the treatment of diabetic macular edema (DME),… Read More »Advernum Biotechnologies Inc., (NASDAQ: ADVM) expects to enrol Phase 2 patients for a treatment for DME using the aflibercept gene.